SCHEMBL22363333

SCHEMBL22363333

c1ccc2sc(-c3ccc4oc(-c5ccc6cc[nH]c6c5)cc4c3)cc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.40
HDAC6 Q9UBN7 1/20 0.39
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
ERN1 O75460 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ALOX5 P09917 1/20 0.36
PRMT3 O60678 1/20 0.35
EHMT2 Q96KQ7 1/20 0.35
PRMT6 Q96LA8 1/20 0.35
PRMT1 Q99873 1/20 0.35
PRMT8 Q9NR22 1/20 0.35
BRD4 O60885 1/20 0.35
CASP3 P42574 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20417352 0.92 APP (0.41) APPHDAC6IKBKBCHUKHSD17B1
SCHEMBL19346119 0.91 HDAC6 (0.43) APPHDAC6IKBKBCHUKCA1
SCHEMBL19217080 0.90 ALOX5 (0.42) APPHDAC6IKBKBCHUKCA1
SCHEMBL13201332 0.85 APP (0.53) APPHDAC6HSD17B1HSD17B2ERN1
SCHEMBL20466823 0.84 HDAC6 (0.43) APPHDAC6IKBKBCHUKCA1
SCHEMBL22222028 0.83 HDAC6 (0.52) APPHDAC6IKBKBCHUKCA1
SCHEMBL20840948 0.81 KDM4E (0.46) APPERN1CA1CA2CA9
SCHEMBL21288060 0.81 CDK8 (0.45) APPADRA2A
SCHEMBL7088340 0.80 ALOX5 (0.54) APPIKBKBCHUKCA1CA2
SCHEMBL22640197 0.78 NPC1 (0.42) APPHDAC6HSD17B1HSD17B2ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10752598-B2 Aryldiazepine derivatives as RSV inhibitors AHR, FURIN, CYP3A5 APP 740/4885HDAC6 115/4885IKBKB 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.